Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
47.91
+0.48 (1.01%)
At close: Dec 5, 2025, 4:00 PM EST
48.43
+0.52 (1.09%)
After-hours: Dec 5, 2025, 6:53 PM EST
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Collegium Pharmaceutical stock ranges from a low of $37 to a high of $50. The average analyst price target of $45.4 forecasts a -5.24% decrease in the stock price over the next year.
Price Target: $45.40 (-5.24%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $45 → $48 | Strong Buy | Maintains | $45 → $48 | +0.19% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $44 → $46 | Strong Buy | Maintains | $44 → $46 | -3.99% | Nov 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | -3.99% | Oct 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | -8.16% | Aug 11, 2025 |
| Piper Sandler | Piper Sandler | Hold Reiterates $36 → $37 | Hold | Reiterates | $36 → $37 | -22.77% | May 9, 2025 |
Financial Forecast
Revenue This Year
797.84M
from 631.45M
Increased by 26.35%
Revenue Next Year
827.14M
from 797.84M
Increased by 3.67%
EPS This Year
7.70
from 1.86
Increased by 314.97%
EPS Next Year
8.23
from 7.70
Increased by 6.85%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 824.0M | 868.4M | ||||
| Avg | 797.8M | 827.1M | ||||
| Low | 763.8M | 761.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 30.5% | 8.8% | ||||
| Avg | 26.4% | 3.7% | ||||
| Low | 21.0% | -4.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 7.98 | 10.59 | ||||
| Avg | 7.70 | 8.23 | ||||
| Low | 7.36 | 6.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 329.8% | 37.4% | ||||
| Avg | 315.0% | 6.9% | ||||
| Low | 296.4% | -10.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.